DNA HYBRIDIZATION IN THE DIAGNOSIS OF INFECTIOUS DISEASE

Information

  • Research Project
  • 3505938
  • ApplicationId
    3505938
  • Core Project Number
    R44AI021213
  • Full Project Number
    2R44AI021213-02
  • Serial Number
    21213
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1984 - 41 years ago
  • Project End Date
    9/29/1987 - 38 years ago
  • Program Officer Name
  • Budget Start Date
    11/1/1985 - 40 years ago
  • Budget End Date
    9/29/1986 - 39 years ago
  • Fiscal Year
    1985
  • Support Year
    2
  • Suffix
  • Award Notice Date
    -
Organizations

DNA HYBRIDIZATION IN THE DIAGNOSIS OF INFECTIOUS DISEASE

The primary goal of this research is to adapt our improved DNA hyridization technology to the identification of select disease agents compatable with current levels of sensitivity of available detection systems. Tests to be developed to commercial kits include Herpes simplex I and II, Cytomegalovirus, Mycobacterium sps., and bacterial/viral agents of infectious diarrhea. The specific aim of this proposal is to develop and clinically evaluate DNA probes and methodology for each disease entity by: 1.) identifying and producing DNA probes for those infectious agents by recombinant DNA techniques; 2.) expand and refine the sensitivity of the detection system using both radiometric and non-radiometric methodologies; 3.) improve the current test methodology. Initial tests will require primary culture. As progress in these three areas is made on improving test sensitivity, our long term objective is to incorporate these advances into a series of new infectious disease diagnostic tests as a result of increasingly greater sensitivity, thus reducing the time necessary for primary culture and ultimately allowing the test to be performed directly on the clinical specimen. Application of DNA probes to infectious disease in this manner should provide unsurpassed accuracy in organism identification. Development of this procedure into a simple, reliable kit has major commercial potential.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    DIAGNOSTIC HYBRIDS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ATHENS
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    45701
  • Organization District
    UNITED STATES